

The proposal incorporates provisions from the following Acts of 2015 regular session: 139; 535; 577; 887; 934; and 1086; and the surviving provisions of Act 301 of 2013. More specifically, the proposal adds and updates definitions from the 2015 Acts; specifies written and other requirements for informed consent and certification requirements for medical emergency exceptions to informed consent; specifies written notarized requirements for consent for minors and women under guardianship; adds policies and procedures requirements for proper storage and disposition of human and fetal tissue, patient follow-up appointments, and patient receipt of USFDA drug labels for abortion-inducing drugs; adds abdominal ultrasound and heartbeat disclosure requirements; adds reporting requirements for child maltreatment/abuse; specifies abortion-reporting requirements; adds adverse event reporting for certain abortion-inducing drugs; adds 48 hour pre-procedure counselling and information requirement; adds requirement that administration of abortion-inducing drugs occurs in same room and physical presence of prescribing physician and requires determination of gestational age and intrauterine location of pregnancy; and introduces signage posting requirements; and comprehensive measures for infection prevention and control. In addition, the proposal adds forms for informed consent; fetal pain; and unemancipated minors and women under legal guardianship or custodianship for incompetency.